Sakamakon cibiyoyi da yawa lokaci III gwaji na asibiti ya nuna cewa idan tsofaffi marasa lafiya da ke fama da cutar sankarar bargo (lymphocytic leukemia) Cll ) ana bi da su tare da sabon maganin ibrutinib da aka yi niyya idan aka kwatanta shi da tsarin da aka fi amfani da shi a baya-bendamustine hade da rituximab An samu raguwar ci gaban cutar na mAb sosai, wanda kuma ya nuna cewa rituximab hade da ibrutinib ba zai kawo ƙarin fa'idodi akan ibrutinib shi kaɗai ba.
CLL shine mafi yawan cutar sankara a cikin tsofaffi. A cikin 2016, FDA ta Amurka ta amince da ibrutinib a matsayin maganin farko na CLL. Karatuttukan da suka gabata sun nuna cewa ibrutinib yafi tasiri fiye da wani maganin chlorramcil, amma babu wani karatu da ya kamanta ibrutinib da bendamustine da rituximab.
Gwajin ya sanya tsofaffi marasa lafiya 547 tare da shekaru matsakaiciyar shekaru 71. An sanya 1/3 bazuwar karɓar bendamustine Tingjia Li rituximab, 1/3 wanda Lu rituximab ya karɓi na Nijia Li, 1/3 shi kaɗai ta hanyar Lu imatinib. Masu binciken sun biyo baya don tsaka-tsakin watanni 38.
Idan aka kwatanta da bendamustine da rituximab (74% a shekaru 2), ibrutinib da rituximab (88% a shekaru 2) da ibrutinib shi kaɗai (2 A shekara, 87%) marasa lafiya suna da ƙimar rayuwa ta rashin ci gaba mai tsayi (ainihin ƙarshen binciken ). Koyaya, binciken bai sami banbanci ba game da yawan rayuwar kungiyoyi uku a shekaru 2.
Idan aka kwatanta da karɓar ibrutinib shi kaɗai, ƙara rituximab zuwa ibrutinib da alama bai inganta hangen nesa ba. Gabaɗaya, marasa lafiya sun amsa da kyau ga duk zaɓuɓɓukan magani uku. Matsakaicin adadin marasa lafiyar da ke karbar bendamustine da rituximab ya kasance 81%, kuma marasa lafiya da ke karɓar ibrutinib da rituximab zuwa 93% na Lu marasa lafiyar da ke karɓar imatinib ya kasance 94%.
Kodayake yawan kawar da cutar sankarar bariki ta amfani da bendamustine tare da rituximab ya kasance mafi girma, wannan bambancin bai fassara zuwa mafi ingancin rayuwa ba ko ƙimar sake dawowa. Don haka sai a kula sosai yayin zabar magunguna.
Koyaya, ibrutinib yana da alaƙa da mahimman sakamako masu illa irin su atrial fibrillation da kuma rashin dacewar zuciya wanda ke ƙara haɗarin bugun jini da sauran cututtukan zuciya. Mai haƙuri yana kula da lura da yanayin zuciya yayin amfani.
https://medicalxpress.com/news/2018-12-ibrutinib-outperforms-chemoimmunotherapy-older-patients.html
